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"Absolute certainty in diagnosis is unattainable, no matter how much information we 
gather, how many observations we make, or how many tests we perform. Our task is not to 
attain certainty, but rather to reduce the level of diagnostic uncertainty enough to make 
optimal therapeutic decision" 
 J.P. Kassirer,  The New England Journal of Medicine, 1989 
1. Introduction 
1.1 Imaging   
As previously described, the majority of patients with sarcoidosis are asymptomatic. The 
main reason patients seek medical attention is an abnormal imaging study.  By far the most 
common situation is a chest radiography that was performed for an alternative diagnosis or 
as a routine procedure before anesthesia or surgery.  
In recent years the increased use of computed tomography (CT) in various screening 
programs for malignancy (colon, lung) or in cardiology has led to an explosion of “lung 
abnormalities,” many of which are eventually attributed to sarcoidosis.  For example, 25% of 
solitary pulmonary nodules (SPN) on chest CT were attributable to “nonspecific 
granulomas” after tissue biopsy (Albert and Russell 2009).  
The recent report of the National Lung Screening Trial in USA favors a CT scan program 
for reducing the all cause mortality attributable to lung cancer (The National Lung 
Screening Trial Research Team 2011). This recommendation is expected to dramatically 
increase the number of chest CT examinations performed for screening purposes. It is 
likely that many of the abnormalities found in the lung parenchyma will undergo biopsy 
and be diagnosed as granulomatous sarcoid-like lesions.  A practical approach to their 
management is needed. 
From a historical perspective, the suspicion of sarcoidosis is typically initiated by abnormal 
imaging.  In fact, the pragmatic “Statement on Sarcoidosis” dedicates a subchapter to this 
issue in the “patient without histology” (Hunninghake et al. 1999). The authors claim that 
clinical and/or radiological features alone may be diagnostic for patients with stage I 
disease (98% reliability) or stage II (89% reliability), but less accurate for stage III (52% 
reliability).  In a review of 100 patients with bilateral hilar lymphadenopathy, sarcoidosis 
was diagnosed if symptoms were limited to uveitis or erythema nodosum or in 
asymptomatic patients with a negative physical examination (74% of all patients).  In these 
patients, the authors conclude that biopsy confirmation is not necessary. 
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1.2 The chest radiograph 
The classical staging system for sarcoidosis progression was described more than 50 years 
ago by Scadding.  In a modified version it includes: 
- stage 0 : no adenopathy or infiltrate  
- stage I :  hilar and mediastinal adenopathy alone 
- stage II :  adenopathy and pulmonary  infiltrates 
- stage  III :  pulmonary infiltrates alone 
- stage  IV :  pulmonary fibrosis  (Scadding 1961) 
 
 
Fig. 1. Stage I sarcoidosis on chest radiography 
 
 
Fig. 2. Stage II parenchymal change on Chest CT 
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Fig. 3. Stage III sarcoidosis on chest radiography 
 
 
Fig. 4. Lymph node calcifications in sarcoidosis on Chest CT(contributed by Dr. Judith 
Rosenman, The Radiology Department, The Chaim Sheba Medical Center, Tel Aviv, Israel)  
The Scadding staging system has important prognostic significance.  Scadding noticed that 
stage I patients have more than 90% resolution of their radiographic findings within 2 years, 
while those with stage III disease demonstrate resolution in less than 1/3 of cases.   
However, the chest radiograph does not correlate well with sarcoidosis symptoms (e.g. 
dyspnea) or functional parameters such as spirometry nor the six-minute walk test (Yeager 
et al. 2005; Judson et al. 2008; Baughman, Sparkman, and Lower 2007).  Furthermore, there is 
poor interobserver reliability among various specialists according to a recent study of chest 
roentgenograms in sarcoidosis patients during a trial of infliximab (Baughman et al. 2009). 
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The characteristic histology of sarcoidosis is the granuloma formation.  Granulomas may be 
seen along the lymphatics of the bronchovascular bundle, interlobular septa, major fissures 
and subpleural areas. These are the anatomic areas that deserve attention on regular chest X 
rays. The majority of patients present with stage I disease in which the differential diagnosis 
includes lymphoma, infectious diseases (fungal, mycobacterial) or occupational diseases 
(beryliosis) and support the need for biopsy confirmation. 
Specific situations may preclude the need for biopsy based on radiologic and clinical 
findings alone. Examples include the Lofgren syndrome (bilateral hilar adenopathy, 
erythema nodosum, fever and arthritis), the Heerfodt syndrome (uveitis, fever and 
parotiditis) and the presence of isolated bilateral hilar adenopathy on the chest radiography 
in a asymptomatic patient.  Furthermore, the Gallium 67 scan may demonstrate the typical 
“Panda sign” (Heerfodt syndrome) or “Lambda sign” (Lofgren syndrome) providing further 
support for these diagnoses and avoiding the need for histological diagnosis. 
1.3 Computed Tomography (CT) scanning 
With recent advances in computed tomography technology, especially the high resolution 
multi-slice CT scan (HRCT), the diagnostic imaging of sarcoidosis has improved. Nishino et 
al. describes the broad spectrum of pulmonary sarcoidosis and clues for the HRCT 
interpretation (Nishino et al. 2010). Disease manifestations are classified as parenchymal, 
airway involvement, mediastinal and hilar adenopathy and complications. 
1.3.1 Parenchymal change  
Nodules are the main feature of this type of interstitial lung disease. They are small (1-3 
mm), peripheral in distribution and typically involve the bronchovascular bundle and 
interlobar septa.  In our practice we use involvement of the major and minor fissures as a 
typical feature of pulmonary sarcoidosis. Nodules typically involve the upper lobes and 
lead to distortion of lung parenchyma. Less frequently, pulmonary sarcoidosis may manifest 
as multifocal opacities of various sizes (cm) described as “the sarcoid galaxy sign” (Nakatsu 
et al. 2002). 
Fibrotic changes are not specific for sarcoidosis, and may represent the end stage of various 
interstitial lung diseases. While a honeycomb pattern is not common in fibrotic sarcoidosis 
(Abehsera et al. 2000), we believe fibrotic changes should discourage a decision for 
histological diagnosis since therapy at this stage is unlikely to affect disease evolution.   
Another supportive sign of pulmonary sarcoidosis is the air trapping at end expiration on 
CT.  In a comparative study of sarcoidosis patients with and without a history of smoking, 
the air-trapping sign was present in the majority of cases (Terasaki et al. 2005).      
1.3.2 Airway involvement 
A minority of patients with lung sarcoidosis may present with airway involvement.  The small 
airways- lobar and subsegmental bronchi- are most commonly affected while, less frequently, 
disease of the large airways may manifest as tracheomalacia (Lenique et al. 1995). 
1.3.3 Mediastinal and hilar lymphadenopathy  
This is the main radiologic feature of sarcoidosis. Symmetric hilar adenopathy is the most 
typical followed by disease in the subcarina and paratracheal lymph nodes stations. 
Calcification and necrosis are rare features in sarcoidosis (Figure 4). 
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1.3.4 Complications                                                      
Hawtin et al describes sarcoidosis as the “great pretender (Hawtin et al. 2010).  ”  Atypical 
features of sarcoidosis may lead to an incorrect diagnosis and treatment.  Challenging 
examples include: 
- Aspergillosis/aspergilloma may complicate sarcoidosis 
- Cavity formation may appear in large nodules due to ischaemic necrosis. Mycetoma 
may also complicate it (Rohatgi and Schwab 1980). 
- Pleural disease including effusion occur in only 2% of cases. Chylothorax and 
pneumothorax were described in case reports (Huggins et al. 2006). 
- Large vessel (venous/arterial) involvement is the result of external compression  while 
necrotising angiitis on small vessels raises the possibility of other vasculitides (like 
Wegener’s disease) 
- Lymphangitis on lung imaging raises the possibility of malignancy. The typical 
interlobular septal thickening is less marked in sarcoidosis than in lymphangitic 
carcinomatosis (Shadid and ter Maaten 2002). 
- Cystic air spaces may be described in stage IV disease. They have a central distribution 
(in contrast to the peripheral honeycomb pattern of usual interstitial pneumonitis, UIP)  
and predominate in the upper lobes (Morello, Ali, and Cesani 1998). 
- Diffuse mediastinal infiltration with compression of adjacent structures (Devaraj et al. 
2007). 
- Pulmonary veno-occlusive disease (POVD) is described in the absence of lung fibrosis 
(Nunes et al. 2006).  Features include a high occurrence of ground glass attenuation in 
patients with pulmonary non-fibrotic sarcoidosis and pulmonary hypertension (sarcoid 
vasculopathy). 
- “Vanishing lung disease” may mimic severe bullous emphysema mainly of the upper 
lobes (Judson 1998). 
Radiologic changes provide a target for various examinations including tissue biopsy, 
bronchoalveolar lavage (BAL) for cytology or bacteriology investigation etc.  However, the 
radiographic changes are not always sufficient to provide a target with significant yield.  
Metabolic activity at the site of the targeted lesions is essential for diagnosis and two 
modalities may be used for this purpose: Gallium isotope scanning or a PET examination. 
1.4 Nuclear medicine 
Gallium 67 scanning is one of the oldest radionuclide imaging techniques used for 
sarcoidosis diagnosis. This isotope is taken up in lesions having an inflammatory or 
infectious cause producing an increased blood flow.  Its sensitivity ranges from 60 to 90% 
and appears as two distinct patterns: 
- the “lambda pattern”: bilateral symmetrical uptake in the parahilar and infrahilar 
lymph nodes and right parahilar lymph node 
- the “panda pattern”: symmetrical uptake in the parotid, lacrimal and salivary glands 
The presence of both patterns is regarded as highly specific for sarcoidosis (Nunes et al. 
2007). 
The uptake of Gallium 67 may be noticed in other organs including the liver and spleen, but 
this abnormal uptake has low sensitivity and specificity. The usefulness of Gallium 67 as a 
marker of disease activity is controversial (Mana 2002). Gallium 67 scanning is a time-
consuming procedure requiring up to 48-72 hours for completion and diagnosis.  It is also 
an expensive diagnostic tool requiring isotope availability (Sulavik et al. 1990).      
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The [18F]-fluorodeoxyglucose-positron emission tomography (FDG-PET) is a non-invasive 
imaging technique widely used in oncology for the evaluation of active metabolic 
malignancy. Since inflammatory cells, such as neutrophils, activated macrophages and 
lymphocytes, also have increased FDG uptake FDG-PET is useful for both the diagnosis 
and/or therapeutic response in sarcoidosis.            
FDG uptake in sarcoidosis was described in the early ’90 s but considered neither 
sufficiently sensitive in uptake intensity nor specific since the pattern is also seen in 
lymphoma and diffuse metastatic disease (Lewis and Salama 1994).  Moreover, PET-CT 
scans are not universally available and are expensive.  The identification of potential biopsy 
sites is the main indication we recommend the use of either PET-CT or Gallium 67 scanning 
(depending on institution availability). 
In a small retrospective study, Braun et al. compared the clinical utility of FDG-PET/CT and 
Gallium 67 scanning in biopsy-proven sarcoidosis. FDG-PET was able to provide a complete 
morpho-functional mapping of the inflammatory active areas and follow therapy response 
in patients with sarcoidosis (Braun et al. 2008). In a larger study, PET-CT helped direct the 
biopsy procedure and diagnose disease in difficult to reach areas such as the heart (Hollister 
et al. 2005).  Cardiac sarcoidosis has a specific pattern and, represents, one of the main 
indications for PET-CT imaging in sarcoidosis. It may also be performed in patients with 
pacemakers. In one series, up to 40% of sarcoidosis patients had cardiac involvement based 
on MRI or PET-CT scanning.  However, these were asymptomatic patients and the need for 
specific therapy was controversial (Mehta et al. 2008). 
The need for differentiating malignant lesions from inflammatory/sarcoid lesions led to the 
use of different tracers.  In a recent study from Japan, the fluorine 18 alpha methyl tyrosine 
tracer was used in positron emission tomography and was able to differentiate malignancy 
(high uptake) from sarcoidosis (negative uptake) (Kaira et al. 2007). 
In conclusion, imaging is a key component in the evaluation of suspected sarcoidosis.   The 
“classical” findings on chest radiographs and CT scans suggest the diagnosis while nuclear 
imaging techniques help target sites for biopsy and assess disease activity. However, results 
should be regarded with caution when considering therapeutic decisions because the 
natural history of disease is extremely variable and prognostic factors for progression of 
disease are lacking. Therefore, atypical radiographic presentation will usually require 
histological diagnosis and correlation with other diagnostic methods help decrease 
diagnostic uncertainty (see further in this chapter).  
2. Pulmonary Function Tests (PFT)  
As more than 90% of patients with sarcoidosis present with lung involvement, it is 
reasonable that pulmonary function tests (PFT), both static and at exercise, are affected.  As 
mentioned in previous sections for other diagnostic tests, these PFT changes are not specific.        
We use PFT for two main purposes: 
- establish the disease severity 
- establish the disease activity and response to therapy 
A pattern of both restrictive and obstructive defects has been described.  In the ACCESS  
study, 14-20% of the enrolled patients had a restrictive pattern and up to 13.6% had a forced 
vital capacity (FVC) of less than 70% on spirometry (Baughman et al. 2001).  The obstructive 
pattern was often described in the African American population (Sharma and Johnson 1988). 
We have also noticed this mixed pattern in one of our patients of African Israeli origin. 
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The explanation of the obstructive pattern may be related to the endobronchial involvement 
by sarcoidosis or to airways hyperreactivity. This last phenomenon was described in up to 
80% of patients with sarcoidosis, depending on the study design and patient selection 
(Shorr, Torrington, and Hnatiuk 2001).  Symptoms of hyperreactive airways may bring the 
patient to medical attention but a clear connection between symptoms and PFT, especially 
spirometric measurements, was not established. A fixed obstructive pattern on PFT was 
associated with doubling the risk for mortality.  
According to The Statement of Sarcoidosis, abberations of pulmonary function tests are 
found in up to 20% of patients with stage I disease and up to 70% of patients with stages II, 
III and IV disease (Hunninghake et al. 1999).         
Diffusion capacity (DLCO) measurement is characteristic for evaluation of any interstitial 
lung disease.  As a sensitive parameter,  DLCO is a marker of gas exchange impairment due 
to both air and vascular lung architecture disturbances. DLCO measurements are the 
preferred diagnostic tool to predict gas exchange disturbances during moderate exercise in 
patients with sarcoidosis.           
In a retrospective cohort study of patients listed for lung transplantation, the single  
independent prognostic factor for survival was right heart ventricle hemodynamics 
(Arcasoy et al. 2001). This is a consequence of pulmonary hypertension and altered gas 
exchange as showed by other studies (Judson 1998).  Therefore, gas exchange impairment as 
a consequence of vascular bed involvement and pulmonary hypertension may be a more 
sensitive parameter for sarcoidosis severity and activity.  In fact, some authors suggest the 
DLCO measurement is the most sensitive of the pulmonary function tests  in stages II-IV 
disease (Huang et al. 1979).  Conversely, others believe that measuring diffusion capacity is 
not a sensitive indicator of pulmonary pathology in sarcoidosis since lung volume can be 
altered independently of DLCO abnormalities.  It is established that gas exchange at a given 
degree of volume restriction differs in sarcoidosis compared with idiopatic pulmonary 
fibrosis (Dunn et al. 1988).            
What about exercise testing? A retrospective study of 48 patients with biopsy-proven 
sarcoidosis suggests that changes in gas exchange with exercise may be the most sensitive 
physiologic measurement to assess the extent of disease in early radiographic stages of 
sarcoidosis (Medinger, Khouri, and Rohatgi 2001).             
The 6-minute walk test is easy to perform and proved to be useful in disability assessment 
and prognosis in lung diseases.  In a prospective study, 142 patients performed the 6-minute 
walk distance test and were monitored for the lowest oxygen saturation. The 6-minute walk 
distance was reduced in most patients but mainly in those with pulmonary hypertension. 
The only independent predictors of the 6-minute walk distance were the Saint George 
Quality of Life Questionaire (SGRQ) , the forced vital capacity (FVC) and the lowest oxygen 
saturation (Baughman, Sparkman, and Lower 2007).            
The distance-saturation product is a new parameter defined as the product of the 6-minute 
walk distance and the lowest oxygen saturation during the test. This parameter was found 
to be well correlated with a number of factors contributing to reduced test performance. 
These factors are: forced expiratory volume in 1 second (FEV1), partial pressure of oxygen 
PAO2, Borg dyspnea score, gender and pulmonary hypertension. This specific parameter 
was also associated with the degree of fibrosis documented by computed tomography (CT) 
and a positive response to therapy (Alhamad et al. 2010). 
Dyspnea is the most common presentation in early to moderate advanced sarcoidosis.  Up 
to half of patients have disease involvement of the skeletal muscles.  Maximal respiratory 
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muscle force generation has been shown to be a more reliable index of functional work 
capacity than the standard static lung function tests (Kabitz et al. 2006). 
When measuring the impairment of the inspiratory muscle strength with volitional tests (PE 
max, PI max), results may be misleading since these tests are highly dependent on patient 
motivation and cooperation.  The use of non-volitional tests for this purpose may be more 
reliable.  One of these non-volitional tests is the measurement of the twitch-mouth pressure 
during bilateral anterior magnetic phrenic nerve stimulation (Winterbauer and Hutchinson 
1980). 
So what are the most sensitive tests for evaluating sarcoidosis severity and/or disease 
activity? They include the static PFT based on lung volumes and diffusion capacity 
measurements, the exercise tests, hemodynamic evaluation and perhaps the respiratory 
muscle impairment serial measurements. About 30 years ago, Winterbauer and Hutchinson 
formulated some guidelines which we believe are still relevant in today’s clinical practice: 
- Pulmonary function tests data should be corelated with clinical (symptomatic) and 
radiological information 
- There are no known PFT criteria that allow the clinician to predict the natural course of 
lung parenchymal sarcoidosis or response to therapy 
- The best parameters to use for clinical follow up are the vital capacity (VC) and the 
diffusion capacity (DLCO), through sequential measurements (comparing an individual 
with himself through time).   
The vital capacity and diffusion capacity share a common direction of change on sequential 
testing in 2/3 of patients with parenchymal sarcoidosis. The remaining 1/3 show a change 
in only one of the measured functions (Bradley et al. 2008) 
As with all forms of interstitial lung disease, there has never been a formal evaluation of the 
diagnostic accuracy of exercise testing.  In clinical practice, a normal study is useful to 
exclude significant interstitial lung disease in a symptomatic patient with normal rest PFT 
and chest radiography. The role of exercise testing in grading disease severity and prognosis 
is uncertain (Bradley et al. 2008).               
We prefer the 6-minute walking distance test as a tool for clinical follow up and prognostic 
assessment along with hemodynamic evaluation of the pulmonary vascular bed (pulmonary 
hypertension). These measurements combined with sequential vital capacity and diffusion 
capacity measurements comprise a fair use of the pulmonary function tests in the diagnostic 
approach to sarcoidosis.  
3. Biomarkers in sarcoidosis  
Biomarkers are largely used in medicine for the diagnosis and follow up of a therapeutic 
response. Two recently published reviews (Manolio 2003; Tzouvelekis et al. 2005) describe 
the properties of an “ideal” serum biomarker : 
- increase in the presence of disease (high sensitivity) 
- normal levels in the absence of the disease (high specificity) 
- add information on the risk and progression of disease 
- correlate with disease activity  
- correlate with disease extent/burden 
- reproducible ( a low coefficient of variation) 
- easy/inexpensive determination  
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Such an ideal serum biomarker is difficult to find in most of the systemic diseases and 
sarcoidosis is not an exception.  Sarcoidosis is a systemic inflammatory disease and so most 
of the biomarkers are serum markers of disease activity.  They include various cytokines, 
enzymes, soluble cytokine receptors and various proteins. 
Following the widespread use of flexible bronchoscopy and the technique of the 
bronchoalveolar lavage (BAL), a score of immunologic studies were performed on cell 
populations obtained from the respiratory epithelium. They include both bronchial and 
alveolar cell origin. 
In two separate studies, Ziegenhagen et al. described the TNF alpha, released by the 
macrophages, and the serum level of sIL-2R as reliable biomarkers reflecting sarcoidosis 
severity and prognosis (Ziegenhagen et al. 2003). 
In a well-designed retrospective study, the clinical usefulness of various serologic markers 
of inflammation were studied in 185 sarcoidosis patients followed in a dedicated sarcoidosis 
center for 4 years (Rothkrantz-Kos et al. 2003).  Disease severity was assessed by ROC curves 
and logistic regression analyses.  The disease severity was also compared to the lung 
function tests results. The sIL-2R had the largest area under the curve (AUC) in the 
untreated patients. The same parameter had the highest sensitivity, specificity, positive and 
negative predictive values among all the evaluated markers. 
So what is the sIL-2R marker? In sarcoidosis, activated alveolar macrophages produce 
interleukin 1 and 6 (IL-1 and IL-6).  The cytokines stimulate the production of SAA (serum 
amyloid A) and IL-2. The IL-2 production leads to T cell activation which express the IL-2 
receptor on their surface IL-2R and release a soluble form of it in serum (s IL-2R). The s IL-
2R marker was found to be increased in active disease (Muller-Quernheim 1998). 
Another biomarker is derived from the lung epithelium specific proteins. The 
pneumoprotein KL-6 (Krebs von den Lungen) was initially described as a marker of 
sarcoidosis by Kobayashi et al. Increased serum levels of KL-6 indicated alveolitis activity 
and disease severity (Kobayashi and Kitamura 1996). 
In a recent retrospective study from Japan, 43 patients with pulmonary sarcoidosis were 
observed.  The initial serum IL-2R, lysozime and KL-6 levels reflected lymphocytic 
alveolitis. The initial serum KL-6 level was also associated with increased parenchymal 
infiltration (Miyoshi et al. 2010).  This was also demonstrated by a strong correlation 
between the serum IL-2R and KL-6 markers levels and the bronchoalveolar lavage (BAL) 
fluid number of total lymphocytes and CD4. 
By far the most studied and controversial serum marker for sarcoidosis is the angiotensin 
converting enzyme (ACE).  Elevated levels were found in up to 60% of the patients with 
active sarcoidosis (Sharma and Alam 1995). This is an exopeptidase playing a central role in 
the control of blood pressure through conversion of the decapeptide angiotensin I to the 
octapeptide angiotensin II and through bradykinin inactivation. Most of the angiotensin I–
angiotensin II conversion occurs through a single lung passage. ACE activity takes place on 
the luminal surface of the pulmonary endothelium but also on non-pulmonary vascular bed 
(Ng and Vane 1967). 
In his pioneer study from 1975, J. Lieberman measured the serum ACE level in 200 patients 
with chronic lung disease and 200 controls (Lieberman 1975). While the serum ACE level 
was reduced in patients with COPD, CF, tuberculosis and lung cancer, the ACE level was 
significantly higher in sarcoidosis (greater than 2 standard deviation above the mean) for 15 
of 17 patients with the disease. In sarcoidosis patients treated with steroids the level was 
normal.  He concluded that an assay of serum ACE is useful for confirming sarcoidosis 
diagnosis and monitoring therapy. 
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Both ACE and angiotensin II were found in the epithelioid cells of sarcoid granuloma, but 
not in macrophages and monocytes (Pertschuk, Silverstein, and Friedland 1981).  In a review 
article, Studdy and Bird analyzed the value of serum ACE (SACE) in clinical practice. As a 
diagnostic test for sarcoidosis, SACE demonstrated a 84% positive predictive value and 74% 
negative predictive value. They described SACE as a useful tool for measuring both 
pulmonary and extrathoracic sarcoidosis activity. They also suggested SACE as a marker of 
response to corticosteroid therapy since the SACE level became normal in treated patients 
within 4-10 weeks.  However, an elevated SACE activity is not exclusive to sarcoidosis and a 
low SACE level does not exclude the disease (Studdy and Bird 1989). 
Another large study of SACE level in 1,941 sarcoidosis patients demonstrated a positive 
predictive value of 90%, negative predictive value of 60%, sensitivity of 57% and specificity 
of 90% (Baughman, Culver, and Judson 2011). 
In addition to sarcoidosis, other diseases associated with elevated SACE levels include 
disseminated tuberculosis, fungal infections, hyperthyroidism and Gaucher’s disease 
(Baughman, Culver, and Judson 2011). It is believed that the serum ACE level reflects the 
total granulomatous load. This level may be influenced by the presence of specific or non-
specific ACE inhibitors such as albumin and its fragments, fibrinolytic products, insulin 
including its beta chain (Klauser et al. 1979). Immunoassays of ACE concentration avoid this 
problem and allow the calculation of the specific activity of ACE. A radio-immune assay 
was developed and showed a strong correlation with serum ACE activity (Brice et al. 1995). 
However, another study showed that serum ACE level does not correlate with sarcoidosis 
severity (Pietinalho et al. 2000). 
The controversy is furthered by polymorphisms of the ACE gene which lead to changes in 
the serum enzyme level. To elucidate the role of the insertion (I)/deletion (D) 
polymorphism of the ACE gene, a case control study was performed in two different patient 
populations: Afro-Americans and Caucasians.  In Afro–Americans, the increased risk for 
sarcoidosis was 1.30 (95% confidence interval) for ID heterozygotes and 3.17 (95% 
confidence interval CI: 1,50-6,71) for DD homozygotes (Maliarik et al. 1998).  In the study of 
a European white population, no association was found between the ACE I/D 
polymorphism and pulmonary disease activity, fibrosis or progression. The I/D 
polymorphism is not a regulatory variant in this disease (McGrath et al. 2001). 
A non-invasive marker of airway inflammation, especially in patients with asthma, is the 
fraction of end tidal exhaled nitric oxide (FeNO). In a feasibility pilot study, FeNO was used to 
detect and monitor therapy response in patients with sarcoidosis (Choi et al. 2009). These 
exhaled NO measurements were not useful for monitoring disease progression in sarcoidosis. 
An ideal biomarker for sarcoidosis does not exist yet. The main limitation is the insufficient 
sensitivity and specificity of the biomarker.  Practically, ACE activity is still the most often 
used marker for disease activity despite its limitations.  It is relatively cheap and easy to 
perform in a standard laboratory and may support the clinical and radiologic features 
suggestive of a sarcoidosis diagnosis. Its value as a marker for therapeutic response in those 
treated with corticosteroids is debatable. 
4. Histology  
Sarcoidosis is defined as a systemic disorder of non-necrotizing granulomatous 
inflammation in affected organs. Almost any organ may be involved but the lungs and 
intrathoracic lymph nodes are by far the most commonly affected (Saldana 1994). In 
addition to the careful correlation of clinical and radiologic features, the diagnosis requires 
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the histologic confirmation of granulomatous inflammation and the exclusion of known 
causes of systemic granulomatous disorders. It is not an easy task for the pathologist. 
Sarcoidosis is one of modern medicine’s “great mimicker’s.” In addition to important 
alternative diagnoses such as lymphoma, tuberculosis, fungal and other infections, unusual 
presentations include the Guillain-Barre syndrome (Shah and Lewis 2003), metastatic 
Crohn’s disease (Emanuel and Phelps 2008), and even pulmonary embolism (Morello, Ali, 
and Cesani 1998). In the retrospective analysis of 30,000 surgical pathology reports, 3% 
revealed granulomatous lesions of which only 1/3 were considered relevant to the clinical 
diagnosis. Of the primary granulomatous disorders, an estimated 1/3 were attributable to 
infection and sarcoidosis (Woodard et al. 1982).  
This section will focus on the histologic features which support the diagnosis of sarcoidosis 
and available methods in obtaining histologic specimens. 
4.1 Granulomatous inflammation 
 
  
a)                                                  b) 
  
 c)                                                  d) 
  
e)                                                  f) 
Fig. 5. Lung and lymph node biopsies at different magnification demonstrating the typical 
non-necrotizing granulomatous lesions of sarcoidosis (contributed by Marina Perlman, 
M.D., Department of Pathology, The Chaim Sheba Medical Center, Tel Aviv, Israel)  
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A granuloma is the compact aggregation of histiocytes (activated macrophages).  They are 
also named “epithelioid” histiocytes because of their indistinct cell borders with elongated 
nuclei in contrast to typical histiocytes with well-defined borders and round or kidney bean-
shaped nuclei (Mukhopadhyay and Gal 2010). The hematoxylin and eosin (H&E) 
preparation demonstrates the pale pink granular cytoplasm and indistinct cell boundaries 
which appear to merge into one another.  They may fuse to form giant cells in the periphery 
and, less often, in the center of granulomas. These giant cells comprise a large mass of 
cytoplasm with many small nuclei arranged peripherally (Langerhans-type giant cell, Figure 
5b) or hazardly (foreign-type giant cell). 
The two types of granulomas, foreign body granulomas and immune granulomas, are 
distinguished by both appearance and pathogenesis.  Foreign body granulomas are incited 
by relatively inert foreign bodies.  The foreign body is large enough to prevent phagocytosis 
by a single macrophage but its presence does not incite an immune response exemplified  by 
lipioid pneumonia. Typically, foreign body granulomatosis is a reaction to material such as 
talc, sutures, or other fibers.  The foreign object is often visualized in the center of the 
granuloma, especially if viewed with polarized light in which it appears retractile.  
Immune granulomas, in contrast to foreign body granulomas, incite an immune response.  
Macrophages engulf the foreign material then process and present it to T lymphocytes.  The 
activated T lymphoctyes produce cytokines, such as IL-2 and IFN-ϒ, which perpetuate the 
immune response and transform macrophages into epithelioid cells and multinucleate giant 
cells.  These cytokines are essential to both the formation and maintenance of granulomas. 
4.2 Granuloma classification 
Granulomas are classified as either necrotizing or non-necrotizing.  Necrosis occurs when 
the trigger invokes a significant delayed hypersensitivity response or is highly toxic to the 
macrophage.  According to Rosen (Saldana 1994), caseous necrosis refers to the cheeselike 
gross appearance and not to microscopic features. The terms “caseous,” “caseating” and 
“noncaseating” have no diagnostic relevance and may be misleading because of the 
association with tuberculosis. For this reason, granulomas are best reported as necrotizing, 
non-necrotizing, or exhibiting minimal necrosis. 
4.3 Histologic features of sarcoidosis 
Sarcoidosis is classically characterized by discrete, well-formed non-necrotizing epithelioid 
granulomas tightly uniform in their size and stage of development (Saldana 1994). 
Macroscopically, granulomas may coalesce to form small nodules which may be palpable as 
1-2 cm non-caseating consolidations. In chronic disease, the granuloma may be surrounded 
by concentric, lamellated fibrous rims or even replaced by fibrous scars. Classic sarcoidosis 
is also supported by the absence of certain features.  For example, the absence of interstitial 
inflammation in areas without granulomas, the absence of organizing pneumonia, and the 
absence of granulomas within alveoli further characterize classic sarcoidosis.   
The classic granulomas in sarcoidosis are non-necrotizing but the presence of necrosis is not 
uncommon. When necrosis is present, however, it is usually “minute, spotty and 
inconspicuous” affecting the central core of a small proportion of granulomas.  The necrosis 
seen in tuberculosis and other infectious diseases may be indistinguishable from that seen in 
sarcoidosis (Saldana 1994).   
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“Sarcoid reactions” deserve special mention.  These are non-caseating granulomas which are 
morphologically identical to those seen in sarcoidosis yet secondary to a primary process.  
Such reactions have been reported in patients with lymphoma, non-small carcinoma of the 
lung, draining lymph nodes of germ cell neoplasm and even in remote lymph node stations 
(Mehrotra and Dhingra 2010).  Indeed, sarcoidosis may precede malignancy in hematologic 
malignancies (the sarcoidosis-lymphoma syndrome), the full spectrum of solid tumors, and 
as a paraneoplastic syndrome for the associated cancer (Cohen and Kurzrock 2007). 
Intracytoplasmic inclusions are frequently found in sarcoidosis.  Schaumann bodies are 
calcified structures often present within the giant cells.  Colorless, birefringent crystals may 
also be seen within the cytoplasm and often together with Schaumann bodies (Saldana 
1994).  They are reported in up to 88% of cases of sarcoidosis but are nonspecific findings 
and also seen in 62% of beryliosis, and 6% of tuberculosis cases.(Saldana 1994)   
Asteroid bodies are star-like inclusions with 30 or more rays originating from the central 
core.  Less frequent than Schaumann bodies, they are reported in 2-9% of sarcoidosis 
specimens (Saldana 1994). Hamazaki-Wesenberg bodies are giant intracellular and 
extracellular lysosomes seen in both granulomatous and nongranulomatous lymph nodes of 
sarcoidosis as well as other etiologies.  They may be mistaken for fungi because the yellow-
brown pigment may stain positive with methenamine silver and may demonstrate a yeast-
like budding appearance (Ro et al. 1987; Saldana 1994) 
These inclusions, while described in sarcoidosis, are found in many other granulomatous 
diseases such as hypersensitivity pneumonitis, berylliosis, fungal infection, talc, tuberculosis 
and nontuberculosis mycobacterial infection. (Mukhopadhyay and Gal 2010; Reid and 
Andersen 1988). The online atlas of granulomatous diseases by Yale Rosen, M.D is an 
excellent resource to visualize all these features (http://granuloma.homestead.com/). 
In summary, sarcoid granulomatous lesions are compact, uniform non-necrotizing 
epithelioid granulomas which may exhibit a mild degree of focal necrosis and a variety of 
inclusion bodies.  However, no morphologic feature is specific or diagnostic of sarcoidosis. 
4.4 Pulmonary sarcoidosis 
Although any organ may be affected, lung or intrathoracic lymph node involvement is 
present in more than 90 percent of patients with sarcoidosis.   It is the most common 
noninfectious cause of lung granulomas observed by surgical pathologists (Mukhopadhyay 
and Gal 2010). While no finding is pathognomonic for pulmonary sarcoidosis, classic 
features may support the diagnosis while their absence encourages the search for an 
alternative diagnosis.  The varied presentations of pulmonary disease will be described. 
Granulomas are typically found bilaterally in the upper two thirds of the lungs and in areas 
rich in lymphatics (the peribronchial, perivascular and septal regions).  This “lymphatic” 
distribution explains the radiographic appearance which may “mimic” primary neoplasm or 
lymphangitic spread. It also explains the effectiveness of trans-bronchial biopsies in 
demonstrating sarcoid granulomas. In addition, the alveoli, bronchi, pulmonary blood 
vessels, and the pleura may all be involved.  
Alveolitis is the earliest pulmonary lesion and is characterized by a lymphocyte-
predominant interstitial pneumonitis. A high proportion of CD-4 positive cells are found in 
bronchoalveolar lavage (BAL) (Baughman, Lower, and du Bois 2003).   In one study, a 
lymphocyte CD4/CD8 ratio greater than 3.5 showed 53% sensitivity but 94% specificity for 
the diagnosis of sarcoidosis (Costabel 1997).  These CD4+ T cells, activated by a complex 
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network of cytokines and chemokines, infiltrate at sites of disease and may play a role in the 
sarcoid granuloma formation.  In a recent study of sarcoid patients with and without intense 
alveolitis, the percentage of a CD4+ effector T cell was much higher in patients with active 
disease as compared with inactive sarcoidosis (Facco et al. 2011).   
The bronchi may be affected by four different mechanism: 1) extrinsic compression by 
enlarged lymph nodes, 2) granulomatous infiltration in the bronchial mucosa, submucosa 
and peribronchial tissue, 3) endobronchial mass lesion and 4) fibrotic scarring causing 
narrowing and distortion of bronchi.  The entire spectrum of the airway may be involved 
from supraglottic structures and larynx to central and distal airways. 
The supraglottic airway including the nasal passages, oropharynx, supraglottic structures and 
larynx are affected in approximately 6% of sarcoid patients (Baughman et al. 2001).  Nasal 
ulceration may cause anosmia while infiltrative nodular sarcoidosis of supraglottic structures 
may cause stridor or cough. Isolated laryngeal involvement may be misdiagnosed as asthma 
(Bower et al. 1980).  In the larynx, compression of the left pharyngeal nerve by enlarged lymph 
nodes may cause vocal cord paralysis (Jaffe, Bogomolski-Yahalom, and Kramer 1994).   
Involvement of the trachea and main bronchi infrequently cause obstructive symptoms.  In a 
retrospective analysis of 2,500 sarcoidosis patients, only 18 patients were identified with 
significant (defined as >50% of the lumen) endoluminal stenosis of proximal bronchi (ESPB).  
Despite the small number of patients, it is important to note that the group with early 
diagnosis and treatment (<3 months from onset of symptoms) were associated with good 
prognosis in contrast to patients with delayed diagnosis and treatment (>3 months from 
onset of symptoms)(Chambellan et al. 2005). 
In the bronchi, granulomatous lesions most frequently involve the distal bronchial tree and 
develop along the bronchovascular bundle or near the airway with predominance for the 
upper and mid-lung regions.  Various airway abnormalities develop and will be described. 
The most common endobronchial abnormality is mucosal edema, erythema or granularity 
but normal-appearing mucosa does not exclude disease.  Classic endobronchial sarcoidosis 
is characterized by mucosal islands of nodules which appear a waxy yellow or dull gray. 
Coalescence of these nodules is responsible for the cobblestone appearance while 
endoluminal occlusion may mimic an obstructing mass.   
Bronchiolitis may occur early in disease without parenchymal involvement.  However, 
airway distortion and bronchiectasis is more prevalent with progression of parenchymal 
disease. In advanced fibrotic disease, cystic lesions and cavitary disease predispose to 
Aspergillus infection. The development of an aspergilloma may cause hemoptysis and 
massive, life-threatening hemoptysis may occur (Stevens et al. 2000)   
Airway Hyperactivity in patients with sarcoidosis is well described. In the prospective 
evaluation of 42 patients with newly diagnosed sarcoidosis and pulmonary symptoms, 20% 
demonstrated AHR by methacholine challenge. Endobronchial biopsies demonstrated  
nonecrotizing granulomas in 100% of these AHR-positive patients but only 45.5% of patients 
without AHR (Shorr, Torrington, and Hnatiuk 2001).   
In the pulmonary vascular system, sarcoid lesions involve the veins much more frequently 
than the arteries and damage may range from destructive change in the media to stenosis or 
complete obliteration of the lumen (Saldana 1994). Although vascular involvement is 
common, the overall prevalence of pulmonary hypertension is low (5%).  Although most 
affected patients have stage IV radiographic disease, two distinct phenotypes of sarcoidosis 
and pulmonary hypetension (PH) may exist depending on the presence or absence of 
pulmonary fibrosis.   
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In the study of 22 patients with sarcoidosis and pulmonary hypertension, 1/3 developed 
pulmonary hypertension in the absence of pulmonary fibrosis and no other known cause of 
secondary pulmonary hypertension (Nunes et al. 2006).  These patients had near normal or 
mild restrictive spirometry but severely reduced DLCO. These findings suggest that PH in 
these patients may be explained by a specific vasculopathy independent of fibrotic 
destruction of the vascular bed.  According to the authors, the presence of septal lines and 
ground glass opacities on HRCT suggest the possibility of pulmonary vascular occlusive 
disease from granulomatous involvement of the venous walls. These radiographic features 
are shared by pulmonary histiocytosis X, a granulomatous disease with intrinsic venopathy.   
Honeycombing is the end stage of many interstitial diseases including sarcoidosis.  In 
contrast to UIP, honeycombing in sarcoidosis is found predominantly in the upper lung 
zones.  Bronchiectasis and emphysematous change may be seen but few granulomas are 
evident at this late stage.  An important complication of the cystic parenchymal disease is 
the development of aspergillomas, which may cause life-threatening hemoptsysis (Rumbak 
et al. 1996; Wollschlager and Khan 1984). 
 
 
a)   b) 
 
c)   d) 
Fig. 6. Pulmonary sarcoidosis affecting a) the lymphatics b) the bronchiole c) the visceral 
pleura and d) coalescing to form nodular disease.  (Contributed by Yale Rosen, M.D.) 
4.5 The diagnostic approach 
Special clinical situations may preclude the need for tissue biopsy.  These include the 
Lofgren and Heerfodt syndrome as well as isolated bilateral hilar lymphadenopathy in 
asymptomatic patients. As mentioned, the “panda” sign (Heerfodt syndrome) and the 
“lambda” sign (Lofgren syndrome) on Gallium-67 scanning further support the diagnosis of 
sarcoidosis and avoid the need for tissue confirmation.  Excluding these unique clinical 
syndromes, histologic confirmation is required.   
In general, the easiest accessible site is used for tissue biopsy which may include the skin, an 
enlarged superficial lymph node or lacrimal gland.  Non-necrotizing granulomas on a liver 
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or bone marrow biopsy are non-specific and support the diagnosis of sarcoidosis only when 
competing diagnoses such as infection, malignancy or drug reaction have been excluded.   
Pulmonary involvement is seen in 90% of patients with sarcoidosis in which intrathoracic 
lymphadenopathy is the most common finding (Hughes and Hill 2009).  In the absence of an 
easily accessible biopsy site, fibroscopic bronchoscopy is preferred for its relative safety and 
high yield. The various techniques include bronchoscopic alveolar lavage (BAL), 
transbronchial lung biopsy (TBLB), transbronchial needle aspiration (TBNA), and 
endobronchial ultrasound (EBUS)-guided TBNA and will be discussed below. 
In the lung, 75% of granulomas are distributed near or within the connective tissue sheath of 
bronchioles and subpleural spaces, “following the lymphatics” as authors describe 
(Mukhopadhyay and Gal 2010). For this reason, the 1999 Statement on Sarcoidosis 
recommends transbronchial biopsy (TBB) as the procedure of choice in most cases.  
Diagnostic yield ranges from 40 to 90% depending on operator experience, the presence of 
pulmonary infiltrates and if at least four biopsies are performed.   
Endobronchial biopsy may detect noncaseating granulomas in 40-60% of cases even in the 
absence of endobronchial nodules or cobblestone appearance (Bjermer et al. 1991).  
Bronchial washing is recommended for microbiologic evaluation while bronchoalveolar 
lavage (BAL) may provide the study of lymphocyte subpopulations.  In one study, a 
CD4/CD8 ratio >3.5 supports the diagnosis with 94% specificity and 53% sensitivity 
(Costabel 1997; Bjermer et al. 1991).   However, its utility is unclear since some report a low 
yield of 47%(Garwood et al. 2007) while authorities report overlap with other etiologies such 
as infection, malignancy, and other inflammatory disorders (Fishman 2008).  
When traditional bronchoscopic procedures such as EBB and TBB are nondiagnostic, further 
investigation has traditionally included mediastinoscopy for patients with mediastinal 
adenopathy and video-assisted thoracoscopic surgical lung biopsy (VATS) or open lung 
biopsy for patients with pulmonary infiltrates. However, advances in conventional and 
endobronchial ultrasound (EBUS)-assisted transbronchial needle aspiration (TBNA) may 
now avoid the need for surgical biopsy in most patients.  Comparison of these techniques 
will be discussed. 
The potential of EBUS-TBNA was demonstrated in a experienced, tertiary care center 
(Garwood et al. 2007).  Fifty consecutive patients with suspected sarcoidosis underwent 
EBUS-TBNA with rapid on-site cytologic evaluation (ROSE).  Results demonstrate safety (no 
major complications) and efficacy with 85% diagnostic yield.  Lymph node size was not 
limited to >1cm and included nine nodes <1cm with 89% successful aspiration.  Such results 
are impressive and comparable to studies of combined modalities (conventional TBNA and 
TBLB) but without the increased risk of pneumothorax and bleeding.  However, these 
results are limited to experienced tertiary-care centers with the availability of ROSE. 
A randomized controlled trial compared conventional TBNA with EBUS-assisted TBNA in 
patients with clinically suspected Stage I and Stage II sarcoidosis (Baughman et al. 2001).   
ROSE was not provided and lymph node size was limited to >1cm (short axis on CT scan).  
The EBUS-assisted TBNA procedure increased the diagnostic yield by an absolute 30% 
(p<0.05). It was 10.2 minutes longer and more patients (26.9%) received propofol for 
sedation. Complications were limited to moderate bleeding in two conventional TBNA 
attempts. Two observations deserve mention. First, the increased diagnostic yield was 
limited to patients with Stage 1 disease. Second, only 24% of patients in the follow-up period 
received specific treatment for sarcoidosis.  These findings question the need to seek tissue 
confirmation in all patients (to be discussed further). 
A large prospective, “implementation” study was designed to assess the yield of EBUS-
assisted TBNA only after routine bronchoscopic procedures (EBB, TBB and conventional 
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TBNA) were nondiagnostic (Tournoy et al. 2010). ROSE was not available. Bronchial 
washing was routinely performed for microbiologic evaluation.  A definitive diagnosis was 
obtained in 59% by routine bronchoscopy (72% TBB, 26% EBB, 14% TBNA) and 77% by 
EBUS-TBNA following nondiagnostic routine bronchoscopy.  In other words, EBUS-TBNA 
following negative flexible bronchoscopy avoided a surgical procedure in 47 out of 80 
patients. Overall, this implementation strategy provided a definitive diagnosis in 92% of 
patients. Minor complications included minor bleeding, intolerance to the procedure and 
one pneumothorax. 
Despite the advancement in these techniques, the decision to pursue tissue diagnosis must 
be carefully considered especially when the diagnosis of sarcoidosis will not initiate 
treatment. For example, in asymptomatic patients with isolated bilateral hilar 
lymphadenopathy (Stage I disease), the main alternative diagnoses include lymphoma, 
malignancy, tuberculosis and fungal infections.   
The likelihood of these alternative diagnoses may be narrowed.  The probability of fungal 
infections is increased only when travel exposure and geographic location are suggestive. 
Second, the presentation of tuberculosis as bilateral hilar lymphadenopathy is rare (<1%) 
and systemic symptoms are invariably present. Likewise, the presentation of lymphoma is 
rarely asymptomatic nor limited to hilar lymphadenopathy. In fact, the number needed to 
diagnosis Hodgkin’s and Non-Hodgkin’s lymphoma in such patients with asymptomatic, 
isolated hilar lymphadenopathy is estimated at 1 in 3,600 and 1 in 33,000, respectively (Reich 
et al. 1998). For those who underwent mediastinoscopy, 18 patients would experience major 
morbidity and 36 require hospitalization. 
4.6 Summary 
Sarcoidosis is a disorder of unknown origin and definitive diagnosis is never certain. 
Typical cases of Lofgren’s and Heerfodt syndrome do not require histologic confirmation.  
Furthermore, the risk/benefit ratio of histologic confirmation should be carefully considered 
when the likelihood of an alternative diagnosis is low.  When histologic confirmation is 
desired, routine bronchoscopic procedures followed by EBUS or EUS-assisted TBNA, when 
needed, is a relatively safe and effective strategy applicable in most institutions.  
5. Conclusion 
Sarcoidosis is defined as a systemic (multiorgan) granulomatous disease of unknown cause.  
The diagnosis is traditionally established by (1) compatible clinical and radiographic 
features, (2) histologic confirmation of granulomatous inflammation with evidence of 
systemic (multiorgan) disease and (3) the exclusion of systemic granulomatous diseases of 
known cause.  Although histologic evidence is needed from only a single site, clinical 
involvement of more than one system helps exclude local granulomatous reactions to 
foreign bodies, tumor or infections.  
In a consensus opinion of the members of the Steering Committee of the ACCESS study, a 
subjective instrument for determining organ involvement in sarcoidosis was proposed 
(Judson et al. 1999). Criteria for organ involvement in patients with biopsy confirmed 
sarcoidosis were described for commonly involved sites (lung, skin, eyes, liver) and those 
less affected (nervous system, kidney, heart, bone marrow, spleen, salivary glands, ear-nose-
throat area, non thoracic lymph nodes , muscle). Although not validated in large scale 
prospective studies, this instrument helps define the systemic nature of disease without the 
necessity to histologically confirm the presence of non-necrotizing granulomatous 
inflammation outside the lungs.              
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The clinician and the pathologist must work together.  The pathologist’s dilemma is the 
differentiation of sarcoidosis from an alternative cause of granulomatous inflammation. 
 While infection (both fungal and mycobacterial) may be easier to diagnose today with 
molecular-based techniques, other illnesses such as sarcoid-like related granulomatous 
disease, vasculitis, granulomatous lesions of unknown significance (GLUS) or the Blau 
syndrome may be difficult to differentiate.               
The clinician must diligently search for the clinical syndromes described that may provide a 
diagnosis without the need for histologic confirmation. In addition, the clinician must 
consider both the likelihood of an alternative diagnosis and the indications for treatment 
prior to recommending invasive procedures for histologic confirmation. Finally, our goal is 
to limit the degree of uncertainty to the best of our ability since the etiology of sarcoidosis is 
still unknown. This requires a careful, step-wise approach. We propose a practical algorithm 
based on the data provided and our experience that most patients will be referred to the 
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develop sarcoidosis than males. The symptoms of sarcoidosis depend on the organ involved. This book deals
with the diagnosis and treatment of this mysterious disease of unknown etiology.
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